Posted by AI on 2025-09-08 18:48:42 | Last Updated by AI on 2025-09-09 23:55:27
Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 1
Genetic engineering company, eGenesis, has received FDA approval to move forward with human trials of gene-edited pig kidneys, offering hope to the 37 million Americans suffering from chronic kidney disease.
##### The Need for Kidney Transplants
With around 80% of kidney diseases stemming from diabetes, high blood pressure, or glomerulonephritis (a condition where the kidneys become damaged), kidney failure is sadly all too common. And with a mere 17% of these patients finding suitable donors, many sufferers opt for dialysis or a kidney transplant.
This groundbreaking trial could offer a viable solution to the huge disparity between patient need and donor availability.
##### Previous Attempts and Challenges
While the idea of using animal organs to mitigate the organ donor shortage is not new, previous attempts have encountered several roadblocks, including immunological challenges and potential risks of viral infection.
eGenesis aims to sidestep these issues by using gene editing to produce pig organs that are more compatible with humans. Previously, the company successfully demonstrated survival of gene-edited pig kidneys in baboons.
This is a promising development for those suffering from chronic kidney disease and for whom conventional solutions don't work.
##### What's Next?
eGenesis hopes to treat its first patient with a gene-edited pig kidney this year.
Professor Joseph Fraietta, a xenotransplantation expert from Vanderbilt University, remarks on the promising advancements in the field: "I think this is a tremendous achievement that could have a tremendous impact on the field of transplantation... on the incredibly difficult problem of the shortage of organs."
It's hoped that, in the near future, the trials will offer a much-needed lifeline for kidney disease patients.